Abstract
ABSTRACT: Purpose: To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas. Methods: We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15–35 patients with advanced or metastatic esophageal and GEJ carcinomas. Results: 10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m2.
Original language | English (US) |
---|---|
Pages (from-to) | 57-63 |
Number of pages | 7 |
Journal | Cancer Investigation |
Volume | 34 |
Issue number | 2 |
DOIs | |
State | Published - Feb 7 2016 |
Keywords
- Pemetrexed
- cisplatin
- gastroesophageal carcinoma
- radiation
ASJC Scopus subject areas
- Oncology
- Cancer Research